Adipotide

FTPP, prohibitin-targeting peptide-1Metabolic/Weight

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight

MechanismTargets prohibitin on the vasculature supplying white adipose tissue, triggering apoptosis of those vessels and so of the fat they feed.

EffectsIn obese rhesus macaques, roughly 11% body-weight reduction over 28 days with improved insulin sensitivity.

DosingNo human dose established.

Bottom lineA discontinued drug, not an emerging one. The programme was abandoned for kidney injury.

Not a dose · what the literature contains instead

Phase 1 dosing in obese prostate-cancer patients began in 2012; the study was terminated and the programme discontinued in 2019 on dose-limiting kidney toxicity, with no maximum tolerated dose published. The 0.43 mg/kg/day figure that circulates is the macaque dose, not a human one.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Dose-limiting nephrotoxicity ended clinical development — raised creatinine and structural change in renal tubular cells. The therapeutic window between fat loss and kidney injury was too narrow for clinical use. Renal toxicity that looked mild and reversible in animals did not stay that way in humans.

No human interaction data. Any concurrent nephrotoxic agent compounds the known dose-limiting toxicity.

CV 1 of 5 — No cardiovascular outcomes data. Weight loss in primates improved insulin sensitivity, an indirect signal only.